Celluris
Inovo Award

Celluris is a finalist for the Inovo Award – Innovation in Health

Categoria: Institutional
10/09/2024

Celluris has been selected as a finalist for the Inovo Award – Innovation in Health. This recognition highlights the company’s work in developing healthcare solutions, specifically personalized treatments for oncology patients through CAR-T immunotherapy.

The Inovo Award – Innovation in Health is an initiative promoted by Biominas Brasil, in partnership with Sindusfarma and the Brazilian Network of Pharmaceutical Innovation (RBIF). The award aims to recognize startups and small companies with innovative solutions in the health sector and to encourage projects focused on human health. The finalist startups have the opportunity to present at the Brazilian Health Innovation Summit, which will take place in São Paulo from September 9 to 11, 2024.

Celluris will be among the companies presenting during the event. The award ceremony will take place on September 11 at the WTC São Paulo, marking the conclusion of the 3rd Brazilian Health Innovation Summit.

Inovo Award Categories:

  • Innovative Health Company: For startups with market-validated solutions (TRL 6-9).
  • Promising Health Company: For startups in the technology validation phase (TRL 1-5).

Finalist Startups:

  • Aptah: RNA WiCo™ technology for RNA editing and expression control.
  • Celluris: Development of CAR-T immunotherapy for the treatment of oncology patients.
  • Cor.Sync: Point-of-care testing platform to measure troponin in 8 minutes.
  • Hi! Healthcare Intelligence: Platform for treatment and medication information for patients.
  • Huna: Artificial Intelligence analysis for risk identification in chronic diseases and cancer.
  • Kidopi – Medical Informatics Solutions: Tool for symptom evaluation and risk stratification.
  • Neogenys: Molecular diagnosis in oncology, with a focus on risk stratification.
  • Ninsaúde: Artificial intelligence for DICOM image analysis in routine exams.
  • Onkos Molecular Diagnostics: Molecular diagnostics in oncology.
  • XenoBrasil: Research on genetically modified pigs for xenotransplantation.

The selection process involved 63 startups, evaluated by a panel of technical and business experts. The selection was based on criteria outlined in the award’s call for applications.